CompanyKYTXNasdaqEmeryville, CA

Kyverna Therapeutics

Kyverna Therapeutics develops autologous CD19-targeting CAR T-cell therapy for neurologic autoimmune diseases.

SEC EDGAR ClinicalTrials.gov ir.kyvernatx.com

424B3Sep 25Latest SEC filing

Sep 24Latest story

September 2026

Kyverna reports one-year data for miv-cel in stiff person syndrome and myasthenia gravis

Sep 24Clinical readoutKyverna Therapeutics

August 2026

Kyverna reports Q2 2026 results and RMAT nod for miv-cel in progressive MS

Aug 11Quarterly updateKyverna Therapeutics

July 2026

Kyverna and ElevateBio sign commercial supply deal for miv-cel

Jul 27PartnershipKyverna Therapeutics

Kyverna amends Oxford Finance loan facility, pushes back Term A deadline

Jul 9PartnershipKyverna Therapeutics